Given the relatively frequent coexistence of HF in these patients, it is necessary to take into account HF when considering initiating glitazones and, more recently, the doubt that has also been raised regarding the safety of GLP1-Ra in patients with HF-rEF [53]. This evidence concerns the gene GCG and hydrops fetalis.